MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Cencora Inc

Gesloten

SectorGezondheidszorg

355.04 -0.03

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

352.91

Max

355.04

Belangrijke statistieken

By Trading Economics

Inkomsten

-1B

-340M

Verkoop

3.1B

84B

K/W

Sectorgemiddelde

42.931

90.831

EPS

3.84

Dividendrendement

0.66

Winstmarge

-0.406

Werknemers

47,000

EBITDA

-1.1B

150M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+14.07% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.66%

2.20%

Volgende Winsten

4 feb 2026

Volgende dividenddatum

2 mrt 2026

Volgende Ex Dividend datum

13 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

278M

66B

Vorige openingsprijs

355.07

Vorige sluitingsprijs

355.04

Nieuwssentiment

By Acuity

17%

83%

14 / 361 Rangschikking in Healthcare

Cencora Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 jan 2026, 23:29 UTC

Populaire aandelen

Stocks to Watch: Atossa Therapeutics, Union Pacific

17 jan 2026, 15:06 UTC

Acquisities, Fusies, Overnames

Trump Purchased Netflix, Warner Bonds in Days After Deal Announcement -- Update

17 jan 2026, 10:30 UTC

Winsten

Supersize CEO Pay Packages Aren't Paying Off for Shareholders -- WSJ

17 jan 2026, 03:10 UTC

Acquisities, Fusies, Overnames

Trump Purchased Netflix, Warner Bonds In Days After Deal Announcement -- WSJ

16 jan 2026, 22:48 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 jan 2026, 22:43 UTC

Acquisities, Fusies, Overnames

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 jan 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 jan 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

16 jan 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Auto & Transport Roundup: Market Talk

16 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

16 jan 2026, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

16 jan 2026, 21:48 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 jan 2026, 21:41 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 jan 2026, 21:38 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 jan 2026, 20:44 UTC

Winsten

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 jan 2026, 20:42 UTC

Marktinformatie

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 jan 2026, 20:28 UTC

Marktinformatie

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 jan 2026, 19:12 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 jan 2026, 18:53 UTC

Marktinformatie

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 jan 2026, 18:41 UTC

Marktinformatie

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 jan 2026, 18:31 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 jan 2026, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

16 jan 2026, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

16 jan 2026, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

16 jan 2026, 17:03 UTC

Marktinformatie

Global Equities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Cencora Inc Prognose

Koersdoel

By TipRanks

14.07% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 404.78 USD  14.07%

Hoogste 440 USD

Laagste 371 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cencora Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

9

Buy

1

Hold

0

Sell

Sentiment

By Acuity

14 / 361 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Cencora Inc

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
help-icon Live chat